Company Contents
Quick Facts & Snapshot
Summary
The Carrier Screening market is entering a high-growth phase, expanding from US$ 2.40 Billion in 2025 to US$ 6.82 Billion by 2032 at a 16.20% CAGR. Scaling reproductive genetic testing, payer coverage, and guideline updates are accelerating adoption, while leading Carrier Screening market companies consolidate share through broad test menus, automation, and integrated digital genetics platforms.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
The ranking of leading Carrier Screening market companies is based on a composite scoring model combining quantitative and qualitative criteria. Core metrics include estimated 2025 carrier screening revenue, multi-year growth trajectory, and share of high-volume accounts such as national reference laboratories, women’s health networks, and academic medical centers. Additional weight is assigned to technology differentiation, including NGS workflows, bioinformatics robustness, panel breadth, and integration of CNV or rare variant detection. Portfolio scope across expanded, ethnicity-based, and universal panels, plus complementary prenatal and preconception offerings, is evaluated. Service coverage, digital ordering platforms, turnaround time, and depth of genetic counseling support influence scores. Strategic factors include M&A activity, geographic expansion, key guideline-aligned collaborations, and ability to win multi-year payer and health-system contracts. Each company receives a normalized score, allowing objective comparison across global and regional players.
Top 10 Companies in Carrier Screening
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Labcorp
Labcorp is a global diagnostics leader providing large-scale reproductive genetic testing, including advanced NGS-based carrier screening and prenatal solutions.
Natera, Inc.
Natera specializes in genomics-based reproductive health, oncology, and organ health tests, with a strong footprint in carrier screening and NIPT.
Quest Diagnostics Incorporated
Quest Diagnostics offers comprehensive diagnostic services with carrier screening integrated into its large women’s health and primary care testing network.
Myriad Genetics, Inc.
Myriad Genetics focuses on hereditary cancer and reproductive genetics, leveraging proprietary variant databases to support accurate carrier screening.
BillionToOne, Inc.
BillionToOne develops molecular counting technologies to deliver highly sensitive NIPT and carrier screening from smaller blood volumes.
Fulgent Genetics, Inc.
Fulgent Genetics offers a broad portfolio of genetic tests, including customizable carrier screening panels for diverse patient populations.
Sema4 (GeneDx Holding Corp.)
Sema4, now aligned with GeneDx, combines genomic testing with deep data analytics across rare disease and reproductive health.
Eurofins Genomics / Eurofins Scientific
Eurofins operates an extensive network of laboratories providing clinical genomics, including carrier screening, across Europe and beyond.
Progenity / Biora Therapeutics (legacy diagnostics business)
Progenity’s legacy diagnostics business continues to support carrier and prenatal screening within selected women’s health channels.
CooperSurgical, Inc.
CooperSurgical delivers fertility, IVF, and women’s health solutions, bundling preconception carrier screening with clinical services.
SWOT Leaders
Labcorp
SWOT Snapshot
Extensive laboratory footprint, strong payer relationships, broad women’s health portfolio, and high-throughput NGS capabilities.
Complex legacy IT infrastructure and sometimes slower innovation cycle than specialized genomics firms.
Expanding universal carrier screening guidelines and integrated employer benefits for reproductive health.
Price pressure from specialized labs and potential reimbursement cuts in key U.S. markets.
Natera, Inc.
SWOT Snapshot
Strong brand in reproductive genomics, advanced bioinformatics, and integrated NIPT plus carrier testing platform.
High R&D and sales expenses with ongoing pressure to demonstrate economic value to payers.
International expansion, broader guideline endorsements, and deeper partnerships with fertility networks.
Competitive innovation from other NGS players and evolving regulatory scrutiny on lab-developed tests.
Quest Diagnostics Incorporated
SWOT Snapshot
Massive national physician reach, robust logistics, and integrated diagnostic portfolio including women’s health.
Perception as generalist reference lab and slower adoption of cutting-edge niche panels.
Embedding carrier screening into routine care pathways and employer wellness programs.
Disintermediation by direct-to-consumer genomics offerings and specialized reproductive genetics labs.
Carrier Screening Market Regional Competitive Landscape
North America remains the largest Carrier Screening market, driven by guideline endorsements, commercial payer coverage, and high awareness among OB/GYNs. Labcorp, Natera, Quest Diagnostics, and Myriad dominate volumes, while BillionToOne and Fulgent Genetics grow rapidly via differentiated technologies and targeted fertility-clinic partnerships.
In Europe, growth centers on Northern and Western markets where public health systems are gradually incorporating expanded carrier screening into preconception care. Eurofins Scientific leverages its pan-European lab footprint, while U.S.-based Carrier Screening market companies selectively expand through local partnerships, focusing on compliance with diverse national reimbursement frameworks.
Asia-Pacific shows accelerating adoption from urban private hospitals and IVF centers, especially in Australia, Singapore, South Korea, and parts of China. Fulgent Genetics and Natera pursue regional collaborations, supporting cross-border fertility tourism. However, fragmented regulation and heterogeneous income levels require tailored panels and flexible pricing from Carrier Screening market companies.
Latin America is an emerging growth frontier, with rising demand from private fertility centers and high-income urban populations in Brazil, Mexico, and Chile. Access remains uneven, favoring Carrier Screening market companies offering cost-effective reduced panels and remote genetic counseling. Partnerships with local diagnostic labs help overcome import barriers and reimbursement constraints.
The Middle East and North Africa region experiences strong interest in carrier screening due to high prevalence of certain recessive disorders and consanguineous marriages. Gulf Cooperation Council countries increasingly fund programs through public or semi-public initiatives. Global Carrier Screening market companies collaborate with regional hospitals and health authorities to tailor panels to local founder mutations.
In Central and Eastern Europe, as well as parts of Africa, market penetration is still early-stage. Pilot projects at academic centers and IVF clinics demonstrate clinical value, but funding gaps persist. Regional diagnostic players often license technology from leading Carrier Screening market companies to build localized offerings and gradually expand access.
Carrier Screening Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Cloud-native genomics company providing low-cost, micro-volume carrier screening leveraging decentralized sample collection and AI-driven variant interpretation.
Develops modular NGS carrier panels optimized for European public health programs, focusing on country-specific founder mutations and high-throughput automation.
Targets IVF and fertility centers with bundled preconception carrier screening, embryo genetic services, and counseling delivered via telehealth platforms.
Offers pan-Asian expanded carrier screening panels tailored to diverse ethnic backgrounds, integrating mobile apps for patient education and consent management.
Provides software-only decision-support tools that plug into existing NGS workflows at Carrier Screening market companies for faster variant classification.
Carrier Screening Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Carrier Screening market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Carrier Screeningmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.